|1.||Li, Juan: 11 articles (08/2014 - 09/2007)|
|2.||Fan, Rong: 9 articles (08/2014 - 09/2007)|
|3.||Pei, Jian-Ming: 8 articles (09/2013 - 04/2006)|
|4.||Wang, Yue-Min: 8 articles (09/2013 - 04/2006)|
|5.||Kaye, Alan David: 7 articles (09/2013 - 04/2009)|
|6.||Guo, Hai-Tao: 7 articles (09/2013 - 04/2006)|
|7.||Xia, Qiang: 7 articles (08/2010 - 06/2003)|
|8.||Yi, Ding-Hua: 6 articles (09/2013 - 09/2007)|
|9.||Yu, Shi-Qiang: 6 articles (09/2013 - 09/2007)|
|10.||Zhang, Shu-Miao: 5 articles (09/2013 - 05/2009)|
|1.||Brain Ischemia (Cerebral Ischemia)
03/01/1993 - "There was no effect on rCBF before MCA occlusion, and the decreased flow after occlusion was enhanced with a significant fall in systemic blood pressure at a dosage of 30 mg/kg. These results indicate that U-50488H has therapeutic potential in cerebral ischemia by mechanisms other than improvement in CBF."
08/01/1994 - "U50488 reduces the severity of tissue damage in a rabbit model of focal cerebral ischemia."
02/14/1991 - "The effect of U-50,488H, a selective kappa-receptor agonist, on memory functions in an animal model of cerebral ischemia was investigated by use of a three-panel runway task. "
02/14/1991 - "Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task."
06/28/2004 - "No difference in pain-related behaviour was found between different peripheral (contralateral, ipsilateral and bilateral) treatments with 0.3 mg U-50,488H. "
11/13/1990 - "doses of 5, 10 and 35 nmol of U-50,488H produced a gradual reduction of pain scores which was statistically significant at all observation periods. "
01/30/1989 - "Since the dorsal raphe nucleus and the region of the central gray pons have been implicated in both analgesia and pain processes a supraspinal site of antinociceptive action of U-50,488H, in addition to a spinal site of action, must be considered."
03/01/2006 - "Contralateral treatment with 0.3 mg U-50,488H into the left hindpaw twice per week reduced the hindpaw oedema, ankle joint inflammation, pain behaviour to mechanical stimuli and severity score of inflammation in the hindpaws of both sides as well as the systemic spread of inflammation to other areas, e.g. "
10/21/2015 - "The aim of this study was to assess the analgesic effects of one of these peptides, named conorphin-1, in comparison with the prototypical KOR-selective small molecule agonist U-50488, in several rodent pain models. "
03/01/2006 - "Left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (LVDP) and maximal velocity of contraction and relaxation (+/-dP/dtmax) were improved when U50488H was administered 1 or 24 h before ischemia (P<0.05). "
08/01/2010 - "[The study of effects and mechanism of U50, 488H on electrical coupling during ischemia in the perfused isolated rat heart]."
11/01/2011 - "U50,488H inhibits neutrophil accumulation and TNF-α induction induced by ischemia-reperfusion in rat heart."
08/01/2010 - "In the prolonged ischemia model, U50, 488H concentration dependently delayed the onset of uncoupling, increased time to plateau, and decreased the maximal rate of uncoupling during ischemia. "
08/01/2010 - "The effect of U50, 488H on electrical coupling parameters including onset of uncoupling, plateau time, slope and fold increase in r(t) was observed in isolated perfused rat heart subjected to global no-flow ischemia. "
01/15/2013 - "U50,488H markedly improved both pulmonary endothelial function (maximal vasorelaxation in response to ACh: 74.9 ± 1.8%, n = 6, P <0.01 vs. hypoxia for 2 wk group) and increased total NO production (1.65 fold). "
07/01/2013 - "Moreover, U50,488H inhibited proliferation of the PASMCs that were induced by hypoxia, and this inhibition lasted for 48 hours in a dose-dependent manner (P < 0.01). "
01/15/2013 - "These results demonstrate that pretreatment with U50,488H attenuates hypoxia-induced pulmonary vascular endothelial dysfunction in an Akt-dependent and NO-mediated fashion."
01/15/2013 - "In cells, U50,488H both increased NO production and reduced hypoxia-induced apoptosis. "
01/15/2013 - "U50,488H (1.25 mg/kg) significantly reduced RVP and RVHI in hypoxia. "
|5.||Spinal Cord Injuries (Spinal Cord Injury)
10/29/1993 - "U-50488H, a selective opioid kappa receptor agonist has been shown to be a neuroprotective agent in animal models of spinal cord injury. "
05/01/1989 - "One hour before a contusive spinal cord injury either compound MK-801 or compound U-50488H was injected intraperitoneally, and a 14-day-delivery osmotic minipump containing the same drug was placed subcutaneously at the time of surgery. "
05/01/1989 - "Neuroprotective effect of MK-801 and U-50488H after contusive spinal cord injury."
12/01/1987 - "Beneficial effects of the kappa opioid receptor agonist U-50488H in experimental acute brain and spinal cord injury."
10/29/1993 - "In this study we examined the effects of U-50488H on post-traumatic vascular injury based on the measurement of vascular permeability, edema and neutrophil infiltration in a rat spinal cord injury model. "
|1.||kappa Opioid Receptors (kappa Opioid Receptor)
|2.||Morphine (MS Contin)
|6.||Thyrotropin-Releasing Hormone (Protirelin)
|10.||Opioid Receptors (Opioid Receptor)